We just got our hands on MindMed’s recent Corporate Overview, an in-depth update on the firm’s development programs. It’s during long stretches between clinical trial phases, as we wait for new announcements from our favorite industry players, that we can take the time to get refreshed on recent developments and company progress.
So let’s take a deeper look at MindMed’s most recent corporate update.
MindMed’s Product Pipeline
Since the industry’s early days, MindMed has been praised for the depth of its product portfolio. Gone are names like Project Lucy, replaced by more pharma-friendly titles like MM-120 and MM-110.
MM-120: MindMed’s LSD program
MM-120 is a proprietary, pharmaceutically optimized form of lysergic acid diethylamide (LSD). It’s MindMed’s lead candidate compound being studied and showing positive results for multiple conditions, in psychiatry, pain, and substance use disorders
Its primary program is LSD for the treatment of anxiety. Initial Phase 2 results were released earlier this year and the outcomes were positive, setting the stage for their upcoming Phase 2b trial.
In January 2022, the U.S. Food and Drug Administration (FDA) cleared their application for the Phase 2b dose-optimization trial of MM-120 for the treatment of GAD.
In December 2021, Study MMED007, a Phase 2a proof-of-concept study, was initiated for the treatment of ADHD. The study is designed to assess the safety and efficacy of repeated low-dose MM-120 administration.
The trial will be conducted in collaboration with the University Hospital Basel in Switzerland and Maastricht University in the Netherlands and is designed to evaluate the therapeutic utility of repeated low doses of LSD.
Additionally, a clinical study of MM-120 in a chronic pain condition is expected to be initiated in Q4 2022.
MM-110: MindMed’s addiction program
Back in 2019, MindMed made one of the first big moves in the psychedelic medicine industry by acquiring a drug candidate based on Ibogaine. The drug was 18-MC, a version of Ibogaine synthesized to be non-hallucinogenic while maintaining the medicine’s anti-addictive properties.
The program hasn’t moved forward as quickly as expected, but we’ve finally received Phase 1 results and are moving forward with plans for Phase 2 this year.
In January 2022, the USAN Council assigned the non-proprietary name “zolunicant”, to MM-110 or 18-MC.
MM-402: MindMed’s MDMA program
From MindMed’s most recent corporate update:
MM-402 or R(-)-MDMA is a synthetic R-enantiomer of MDMA that exhibits feelings of connectedness and compassion. At the moment, MindMed is focused on developing it for the treatment of core symptoms of autism spectrum disorder. Preclinical studies of R(-)-MDMA demonstrate its acute prosocial effects, while its diminished dopaminergic activity suggests that it may exhibit less stimulant activity, neurotoxicity, hyperthermia and abuse liability profile when compared to racemic MDMA.
IND-enabling studies are currently ongoing and, through the Company’s collaboration with University Hospital Basel, a comparative Phase 1 pharmacokinetic/pharmacodynamic trial of R(-)-MDMA, S(+)-MDMA and (+)- MDMA in healthy volunteers is expected to commence in Q3 2022.
You can find a link to the complete corporate overview here.
